We protect your health through science

Investigation

Neisseria, Listeria and Bordetella

Research Lines

Content with Investigacion Inmunopatología del SIDA .

Research Lines:

1.    Molecular mechanisms associated to the protection of HIV-1 infection in limb-girdle muscular dystrophy dominant D2 (LGMDD2) patients.
2.    Generation of neutralizing antibodies for therapeutic use based on the broad-spectrum neutralizing response against founder viruses.
3.    Characterization of the immune memory against SARS-CoV-2 in a population over 65 years of age.
4.    Screening and characterization of new anti-latency drugs against HIV-1.
5.    Study of viral entry and HIV tropism in viruses of special epidemiological relevance in Spain. 
6.    Genetic mechanisms of protection and control of HIV-1 infection in populations with extreme phenotypes.

Clinical studies:

1.    Phase 1 clinical trial to evaluate the safety and immunogenicity of HIV-1 envelope-based 763SIP8/MPLA-5 vaccine as a preventive vaccine in healthy uninfected adults. 
2.    ENE-COVID-Senior: Prospective observational study in a cohort of elderly nursing home residents to establish their immune status after receiving a complete vaccination regimen.

Implementation of new technologies:

1.    Identification of HIV-1 integration sites by deep sequencing.
2.    Single cell transcriptomics with simultaneous TCR/BCR sequencing.
3.    Epidemiological intelligence for prediction of SARS-CoV-2 variants likely to emerge in different vaccination settings.
 

Research projects

Content with Investigacion Inmunopatología del SIDA .

1.    Immune response to SARS-CoV-2 infection: effect in naïve vaccinees and seropositives against the most transmissible variants and relevance of host genetics.
Principal Investigator: Javier García Pérez. 
Funding Agency: Acción Estratégica en Salud Intramural 2021(ISCIII)
Funding: 135.000 €
Duration: 2022-2025. 
Project Reference: PI21CIII/00025.
2.    Design and generation of viral stocks of new SARS-CoV-2 variants (omicron subvariants) and analysis of their susceptibility to antibodies neutralization.
Principal Investigator: Javier García Pérez.
Funding Agency: Hipra Scientific S.L.U.
Funding: 103.771 €
Duration: 2023-2025.
Project Reference: MVP 198/23.
3.    Characterization of a mutation in transportin 3 that protects against HIV infection: molecular mechanisms and discovery of new drugs.
Principal Investigator: José Alcamí y Javier García Pérez.
Funding Agency:     Proyectos de I+D+I, Generación de Conocimiento y Retos Investigación de la Agencia Estatal de Investigación.
Funding: 240.000 €
Duration: 2022-2026. 
Project Reference: PID2021-125978OB-C21 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE

4.    Generation of immunogens based on HIV-1 envelopes from acutely infected individuals with a broad neutralizing response against founder viruses.
Principal investigator: Nuria González Fernández.
Funding Agency: Acción Estratégica en Salud Intramural 2023 (ISCIII)
Funding: 82.000 €
Duration: 2024-2026. 
Project Reference: PI23CIII/00039.
5.    Phase 1 clinical trial to evaluate the safety and immunogenicity of HIV-1 envelope-based 763SIP8/MPLA-5 vaccine. 
Principal Investigator: Josep Mallolas Masferrer.
Funding Agency: Proyectos de Investigación Clínica Independiente, Acción Estratégica en Salud 2021-2023 (ISCIII).
Funding: 173.200 €
Duration: 2024-2026. 
Project Reference: ICI23/00025.
6.    Service of immunological determinations of the ENE-COVID SENIOR II protocol.
Principal Investigator: Mayte Pérez Olmeda y Javier García Pérez. 
Funding Agency: Fundación para la investigación biomédica del Hospital Universitario La Paz
Funding: 185.037 €
Duration: 2024-2025. 
Project Reference: MOTR 219/24.
7.    Characterization of the immune memory against SARS-CoV-2 in a population over 65 years of age using single cell transcriptomics.
Principal Investigator: Javier García Pérez y Francisco Díez Fuertes.
Funding Agency: Acción Estratégica en Salud Intramural 2021(ISCIII)
Funding: 152.000 €
Duration: 2025-2027. 
Project Reference: PI24CIII/00058
8. Evaluation of rimonabant and cannbinooid analogues in HIV infection and viral latency.
Principal Investigator: Luis Miguel Bedoya del Olmo. 
Funding Agency: Universidad Complutense de Madrid
Funding: 12.000 €
Duration: 2024-2025. 
Project Reference: PR12/24-31553.
9. Discovery of new inhibitors of HIV-1 RNA biogenesis based on blocking the ribonucleoprotein RRE-Rev.
Principal Investigator: José Gallego Sala. Associate Researcher: Luis Miguel Bedoya del Olmo
Funding Agency: Department of Innovation, Universities, Science and Digital Society. Generalitat Valenciana.
Funding: 543,683.84 €
Duration: 2025-2027. 
Project Reference: PROMETEO/2021/036.

Publications

Sort
Category

Where are we with monoclonal antibodies for multidrug-resistant infections?

Where are we with monoclonal antibodies for multidrug-resistant infections? McConnell MJ. Drug Discov Today. 2019 May;24(5):1132-1138. doi: 10.1016/j.drudis.2019.03.002.

PUBMED

Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii

Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. Gil-Marqués ML, Moreno-Martínez P, Costas C, Pachón J, Blázquez J, McConnell MJ. J Antimicrob Chemother. 2018 Nov 1;73(11):2960-2968. doi: 10.1093/jac/dky289.

PUBMED

Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection

Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection. Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ. Vaccine. 2018 Jul 5;36(29):4153-4156. doi: 10.1016/j.vaccine.2018.05.113.

PUBMED

Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii

Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii. Carretero-Ledesma M, García-Quintanilla M, Martín-Peña R, Pulido MR, Pachón J, McConnell MJ. Virulence. 2018 Dec 31;9(1):930-942. doi: 10.1080/21505594.2018.1460187.

PUBMED

Content with Investigacion Inmunopatología del SIDA .

List of staff

Additional Information

The Neisseria, Listeria and Bordetella Unit provides support to the National Health System with the aim of improving the health and well-being of citizens, through the development and application of diagnostic and molecular characterization techniques, generating laboratory data essential for the surveillance of infectious diseases covered by the Unit, as well as maintaining lines of research for microbiological and immunological evaluation of vaccines, both in development and those available. 

The Unit has 4 microbiological surveillance programs at the National Center for Microbiology: For invasive meningococcal disease, for gonococcal infection, for listeriosis and for whooping cough. Likewise, the Unit maintains extensive activity in international networks and consortia: it is part of the EU-Ibis consortium for the study of Meningococcal Disease, the EURO-GASP program for the study of antibiotic resistance in gonococcus, the European Listeria typing group network and the European network for Bordetella, all of them coordinated and financed in whole or in part by the ECDC.  

The Unit constitutes the External Reference Laboratory for meningococci of the PAHO/WHO SIREVAII network. Thus, the active lines of research in the Unit respond to the objectives defined both by the support for the National Health System and by the international collaborative work in which it actively participates.

The Neisseria, Listeria and Bordetella Unit provides support to the National Health System with the aim of improving the health and well-being of citizens, through the development and application of diagnostic and molecular characterization techniques, generating laboratory data essential for the surveillance of infectious diseases covered by the Unit, as well as maintaining lines of research for microbiological and immunological evaluation of vaccines, both in development and those available. 

The Unit has 4 microbiological surveillance programs at the National Center for Microbiology: For invasive meningococcal disease, for gonococcal infection, for listeriosis and for whooping cough. Likewise, the Unit maintains extensive activity in international networks and consortia: it is part of the EU-Ibis consortium for the study of Meningococcal Disease, the EURO-GASP program for the study of antibiotic resistance in gonococcus, the European Listeria typing group network and the European network for Bordetella, all of them coordinated and financed in whole or in part by the ECDC.  

The Unit constitutes the External Reference Laboratory for meningococci of the PAHO/WHO SIREVAII network. Thus, the active lines of research in the Unit respond to the objectives defined both by the support for the National Health System and by the international collaborative work in which it actively participates.

Content with Investigacion Inmunopatología del SIDA .